Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations

医学 内科学 肿瘤科 胃肠病学 耐火材料(行星科学) 髓系白血病 队列 临床研究阶段 化疗 生物 天体生物学
作者
Jasleen K. Randhawa,Hagop M. Kantarjian,Gautam Borthakur,Philip A. Thompson,M. Konopleva,Naval Daver,Naveen Pemmaraju,Elias Jabbour,Tapan M. Kadia,Zeev Estrov,Abhijit Ramachandran,Jamil Paradela,Michael Andreef,Mark J. Levis,Farhad Ravandi,Jorge E. Cortés
出处
期刊:Blood [Elsevier BV]
卷期号:124 (21): 389-389 被引量:110
标识
DOI:10.1182/blood.v124.21.389.389
摘要

Abstract Introduction FLT3-ITD (Internal tandem duplication) and FLT3-TKD (tyrosine kinase domain, D835) mutations are frequently seen in AML; FLT3-ITDs are associated with inferior survival. Development of FLT3-TKD mutation during FLT3 inhibitor-therapy is seen in up to 22% of patients and associated with FLT3 tyrosine kinase inhibitor (TKI) treatment failure (Cancer 2014). Crenolanib besylate is an orally bioavailable TKI with activity against both FLT3-ITD and FLT3-TKD mutations. We evaluated the clinical efficacy of crenolanib in relapsed/refractory AML pts with activating FLT3 mutations. Methods This was a single center phase II open label study of crenolanib administered at 200 mg/m2/day three times a day continuously in 28 day cycles. FLT3 mutated pts (either FT3-ITD or FLT3-TKD) with primary AML, therapy-related AML and AML following an antecedent hematological disorder were included. Pts were ≥18 years of age with ECOG PS of 0-2. Pts with CNS disease were excluded. Pts relapsing post-allogeneic stem cell transplant could be included if they were >30 days post-transplant. 38 pts enrolled in 2 parallel cohorts of which 34 were evaluable, 13 in cohort A (FLT3 TKI-naïve) and 21 in cohort B (progressed on prior FLT3 TKI). Results Median age was 61 (30 – 87). Patients had undergone a median of 3.5 prior therapies (range 1 – 8); 38% of pts had diploid and 23% complex cytogenetics. Among patients with available information, NPM1 mutation was identified in 62% (10/16) and DNMT3A in 57% (8/14). Median baseline marrow blast % was 58% (7 – 97%). Of cohort B patients, prior therapy was sorafenib in 57%, quizartinib in 14%, PLX3397 in 5% and midostaurin in 10%. 9% and 5% had received 2 and 3 FLT3 TKIs, respectively. 10 enrolled patients had progressed post-transplant (SCT) (3 allogeneic in cohort A; 6 allogeneic, 1 autologous in cohort B). Median duration of study therapy was 9 wks (range 5 – 24), 2 pts remain on study. Reasons for study cessation were disease progression in 66%, no response in 16%, toxicity in 6%, clinical deterioration due to other co-morbidities in 6%, 3% lost to follow up and 3% to receive SCT. At a median follow up of 14 weeks (wks), ORR was 47%: 12% achieved complete response with incomplete count recovery (CRi), 32% hematological improvement (Hi) (85% of them with >50% decrease in blast count) and 3% morphologic leukemia-free state (MLFS). 21% had progressive disease and 32% no response. The median event-free survival (EFS) was 8 wks and overall survival (OS) was 19 wks for the whole cohort. The response by cohort was: Table FLT3 TKI naïve Prior FLT3 Therapy Response % CRi 23 5 MLFS 8 0 Hi 31 33 NR 31 33 PD 8 29 Median OS 55 wks 13 wks (p=0.027) Median EFS 13 wks 7 wks (p<0.001) Pts achieving marrow response (CRi and MLFS) had superior EFS (median 22 wks vs 8 wks for non-responders, p=0.003), with a trend toward superior OS for the marrow responders (median 55 weeks versus 15 wks, p=0.166). 2 of the 4 pts with FLT3-TKD in cohort A responded (CRi, Hi). Among pts with both mutations, 1/1 pt in cohort A achieved CRi and 5/6 pts in cohort B achieved Hi. EFS and OS were not influenced by complex cytogenetics, number of prior therapies or the presence of NPM1 or DNMT3A mutations. OS and EFS were, for patients with ITD (19 wks; 7 wks), D835 (6 wks; 8 wks) or both FLT3 mutations (12 wks; 9 wks), p=0.908; 0.391 respectively. The main grade 3 toxicities were GI side effects (abdominal pain and nausea). There was no death attributed to treatment related toxicity. Conclusions Crenolanib is a well-tolerated FLT3 TKI with clinical efficacy in heavily pre-treated, relapsed/refractory FLT3 mutated AML patients. The superior results in FLT3 inhibitor-naïve patients suggests that on-target FLT3 inhibition is likely primarily responsible for drug efficacy. Combination therapy (e.g., with chemotherapy or hypomethylating agents) could potentially provide additive efficacy in both treatment-naïve and relapsed/refractory pts. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cm发布了新的文献求助10
1秒前
3秒前
3秒前
3秒前
3秒前
3秒前
大力水手完成签到,获得积分0
5秒前
7秒前
cm完成签到,获得积分10
9秒前
酷炫的听枫完成签到 ,获得积分10
10秒前
吱吱吱完成签到 ,获得积分10
11秒前
12秒前
上善若水呦完成签到 ,获得积分10
12秒前
小羡完成签到 ,获得积分10
12秒前
cqwswfl完成签到 ,获得积分20
13秒前
南山无梅落完成签到,获得积分10
14秒前
啵妞完成签到 ,获得积分10
14秒前
上官若男应助qiqi采纳,获得30
16秒前
拼搏的潘子完成签到,获得积分10
17秒前
zsj完成签到,获得积分10
18秒前
dolesy发布了新的文献求助10
19秒前
执着烧鹅完成签到 ,获得积分10
19秒前
哈哈哈完成签到,获得积分10
21秒前
yar应助博修采纳,获得10
23秒前
可爱的函函应助博修采纳,获得10
23秒前
MchemG应助博修采纳,获得10
23秒前
酷波er应助博修采纳,获得10
24秒前
时代更迭完成签到 ,获得积分10
24秒前
25秒前
WGOIST完成签到,获得积分10
26秒前
九九完成签到 ,获得积分10
26秒前
李新宇完成签到 ,获得积分10
27秒前
大橙子发布了新的文献求助10
31秒前
库凯伊完成签到,获得积分10
31秒前
duckspy发布了新的文献求助10
32秒前
CodeCraft应助jenny采纳,获得10
34秒前
lhnsisi完成签到,获得积分10
35秒前
jhlz5879完成签到,获得积分10
36秒前
悦耳曼凝完成签到 ,获得积分10
37秒前
文静的紫萱完成签到,获得积分10
37秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038157
求助须知:如何正确求助?哪些是违规求助? 3575869
关于积分的说明 11373842
捐赠科研通 3305650
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022